type 1 diabetes

February 2, 2024

Study links small pancreas size to faster progression to stage 3 Type 1 diabetes

The study findings, published in the journal Diabetes Care, suggest that pancreas imaging can have a benefit in tracking disease development and recruitment for preventive and therapeutic trials.

By Jill Clendening
March 23, 2023

Study sheds light on drug’s impact on diabetes progression

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

By Craig Boerner
March 23, 2023

Saunders receives diabetes research innovation award

Vanderbilt’s Diane Saunders, PhD, has been selected as a 2023 recipient of an Innovation Award by the Network of Pancreatic Donors with Diabetes.

By Jill Clendening
When half of their six children were diagnosed with what was then believed to be Type 1 diabetes, David and Ellen Pursell decided their family would participate in research related to the health condition. This family photo from several years ago includes, seated, from left, Peggy, Ramsey and Chrissy. Standing, from left, are Vaughan, Ellen, Martin, David and Parker.
March 9, 2023

Family’s participation key to advancing diabetes research

A study of one family from Alabama has led Vanderbilt researchers to discover that insulin deficiency, independent of the autoimmunity associated with Type 1 diabetes, is the principal factor leading to a markedly smaller pancreas.

By Jill Clendening
November 21, 2022

Vanderbilt mourns loss of former Rheumatology director Thomas

James Ward “Tom” Thomas II, MD, former director of Vanderbilt’s Division of Rheumatology and Immunology, died Nov. 16 following a battle with cancer. He was 74.

By Doug Campbell
William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

By Jill Clendening
November 11, 2021

International gathering scrutinizes immune response, beta cell biology in Type 1 diabetes

By Jill Clendening
August 24, 2021

Autoimmunity advance

Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.
By Leigh MacMillan
August 5, 2021

Gene expression in diabetic nephropathy

Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.
By Shivani Sharma
March 4, 2021

Targeting glucagon action in diabetes

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.
By Leigh MacMillan
August 22, 2019

Discovery may point to better treatments for Type 1 diabetes

Researchers have made a paradigm-shifting discovery that could lead to new treatments, better health and longer life for patients with Type 1 diabetes.
By Bill Snyder
June 9, 2019

Study drug delays type 1 diabetes in high risk children and adults

Drug delays onset of type 1 diabetes by two years
By Craig Boerner
September 13, 2018

Healthy antibodies reverse diabetes

Vanderbilt researchers have discovered that IgM-type antibodies appear to play a protective role to prevent the development of type 1 diabetes — and that purified IgM antibodies can reverse the disease.
By Leigh MacMillan
1 2